279 related articles for article (PubMed ID: 35008399)
1. Contribution of LAT1-4F2hc in Urological Cancers via Toll-like Receptor and Other Vital Pathways.
Zhao X; Sakamoto S; Maimaiti M; Anzai N; Ichikawa T
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008399
[TBL] [Abstract][Full Text] [Related]
2. Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex.
Yan R; Zhao X; Lei J; Zhou Q
Nature; 2019 Apr; 568(7750):127-130. PubMed ID: 30867591
[TBL] [Abstract][Full Text] [Related]
3. The human LAT1-4F2hc (SLC7A5-SLC3A2) transporter complex: Physiological and pathophysiological implications.
Kahlhofer J; Teis D
Basic Clin Pharmacol Toxicol; 2023 Nov; 133(5):459-472. PubMed ID: 36460306
[TBL] [Abstract][Full Text] [Related]
4. Yeast Cell-Based Transport Assay for the Functional Characterization of Human 4F2hc-LAT1 and -LAT2, and LAT1 and LAT2 Substrates and Inhibitors.
Kantipudi S; Fotiadis D
Front Mol Biosci; 2021; 8():676854. PubMed ID: 34124158
[TBL] [Abstract][Full Text] [Related]
5.
Kantipudi S; Harder D; Bonetti S; Fotiadis D; Jeckelmann JM
Methods Protoc; 2021 Jul; 4(3):. PubMed ID: 34449687
[TBL] [Abstract][Full Text] [Related]
6. Targeting L-type amino acid transporter 1 in urological malignancy: Current status and future perspective.
Pae S; Sakamoto S; Zhao X; Saito S; Tamura T; Imamura Y; Sazuka T; Reien Y; Hirayama Y; Hashimoto H; Kanai Y; Ichikawa T; Anzai N
J Pharmacol Sci; 2022 Dec; 150(4):251-258. PubMed ID: 36344047
[TBL] [Abstract][Full Text] [Related]
7. Characterization of substrates and inhibitors of the human heterodimeric transporter 4F2hc-LAT1 using purified protein and the scintillation proximity radioligand binding assay.
Kantipudi S; Harder D; Fotiadis D
Front Physiol; 2023; 14():1148055. PubMed ID: 36895635
[TBL] [Abstract][Full Text] [Related]
8. L-type amino acid transporter-1 expressed in human astrocytomas, U343MGa.
Asano S; Kameyama M; Oura A; Morisato A; Sakai H; Tabuchi Y; Chairoungdua A; Endou H; Kanai Y
Biol Pharm Bull; 2007 Mar; 30(3):415-22. PubMed ID: 17329830
[TBL] [Abstract][Full Text] [Related]
9. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas.
Okubo S; Zhen HN; Kawai N; Nishiyama Y; Haba R; Tamiya T
J Neurooncol; 2010 Sep; 99(2):217-25. PubMed ID: 20091333
[TBL] [Abstract][Full Text] [Related]
10. The Heavy Chain 4F2hc Modulates the Substrate Affinity and Specificity of the Light Chains LAT1 and LAT2.
Kantipudi S; Jeckelmann JM; Ucurum Z; Bosshart PD; Fotiadis D
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066406
[TBL] [Abstract][Full Text] [Related]
11. Significance of system L amino acid transporter 1 (LAT-1) and 4F2 heavy chain (4F2hc) expression in human developing intestines.
Ohno C; Nakanishi Y; Honma T; Henmi A; Sugitani M; Kanai Y; Nemoto N
Acta Histochem Cytochem; 2009 Jun; 42(3):73-81. PubMed ID: 19617954
[TBL] [Abstract][Full Text] [Related]
12. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models.
Ohkame H; Masuda H; Ishii Y; Kanai Y
J Surg Oncol; 2001 Dec; 78(4):265-71; discussion 271-2. PubMed ID: 11745822
[TBL] [Abstract][Full Text] [Related]
13. The complete assembly of human LAT1-4F2hc complex provides insights into its regulation, function and localisation.
Wu D; Yan R; Song S; Swansiger AK; Li Y; Prell JS; Zhou Q; Robinson CV
Nat Commun; 2024 May; 15(1):3711. PubMed ID: 38697966
[TBL] [Abstract][Full Text] [Related]
14. The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2.
Maimaiti M; Sakamoto S; Sugiura M; Kanesaka M; Fujimoto A; Matsusaka K; Xu M; Ando K; Saito S; Wakai K; Imamura Y; Nakayama K; Kanai Y; Kaneda A; Ikehara Y; Ikeda JI; Anzai N; Ichikawa T
Sci Rep; 2021 Jun; 11(1):11478. PubMed ID: 34075107
[TBL] [Abstract][Full Text] [Related]
15. Association of 4F2hc with light chains LAT1, LAT2 or y+LAT2 requires different domains.
Bröer A; Friedrich B; Wagner CA; Fillon S; Ganapathy V; Lang F; Bröer S
Biochem J; 2001 May; 355(Pt 3):725-31. PubMed ID: 11311135
[TBL] [Abstract][Full Text] [Related]
16. Expression of amino acid transporter LAT1 and 4F2hc in the healing process after the implantation of a tooth ash and plaster of Paris mixture.
Kim SG; Ahn YC; Yoon JH; Kim HK; Park SS; Ahn SG; Endou H; Kanai Y; Park JC; Kim DK
In Vivo; 2006; 20(5):591-7. PubMed ID: 17091765
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of substrate transport and inhibition of the human LAT1-4F2hc amino acid transporter.
Yan R; Li Y; Müller J; Zhang Y; Singer S; Xia L; Zhong X; Gertsch J; Altmann KH; Zhou Q
Cell Discov; 2021 Mar; 7(1):16. PubMed ID: 33758168
[TBL] [Abstract][Full Text] [Related]
18. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precusor lesions.
Kim DK; Ahn SG; Park JC; Kanai Y; Endou H; Yoon JH
Anticancer Res; 2004; 24(3a):1671-5. PubMed ID: 15274339
[TBL] [Abstract][Full Text] [Related]
19. Molecular events involved in up-regulating human Na+-independent neutral amino acid transporter LAT1 during T-cell activation.
Nii T; Segawa H; Taketani Y; Tani Y; Ohkido M; Kishida S; Ito M; Endou H; Kanai Y; Takeda E; Miyamoto Ki
Biochem J; 2001 Sep; 358(Pt 3):693-704. PubMed ID: 11535130
[TBL] [Abstract][Full Text] [Related]
20. Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma.
Kaira K; Kawashima O; Endoh H; Imaizumi K; Goto Y; Kamiyoshihara M; Sugano M; Yamamoto R; Osaki T; Tanaka S; Fujita A; Imai H; Kogure Y; Seki Y; Shimizu K; Mogi A; Shitara Y; Oyama T; Kanai Y; Asao T
Hum Pathol; 2019 Feb; 84():142-149. PubMed ID: 30300664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
